The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
Open accessAbstract
Mutations in the genes encoding isocitrate dehydrogenase, IDH1 and IDH2, have been reported in gliomas, myeloid leukemias, chondrosarcomas and thyroid cancer. We discovered IDH1 and IDH2 mutations in 34 of 326 (10%) intrahepatic cholangiocarcinomas. Tumor with mutations in IDH1 or IDH2 had lower 5-hydroxymethylcytosine and higher 5-methylcytosine levels, as well as increased dimethylation of histone H3 lysine 79 (H3K79). Mutations in IDH1 or IDH2 were associated with longer overall survival (P=0.028) and were independently associated with a longer time to tumor recurrence after intrahepatic cholangiocarcinoma resection in multivariate analysis (P=0.021). IDH1 and IDH2 mutations were significantly associated with increased levels of p53 in intrahepatic cholangiocarcinomas, but no mutations in the p53 gene were found, suggesting that mutations in IDH1 and IDH2 may cause a stress that leads to p53 activation. We identified 2309 genes that were significantly hypermethylated in 19 cholangiocarcinomas with mutations in IDH1 or IDH2, compared with cholangiocarcinomas without these mutations. Hypermethylated CpG sites were significantly enriched in CpG shores and upstream of transcription start sites, suggesting a global regulation of transcriptional potential. Half of the hypermethylated genes overlapped with DNA hypermethylation in IDH1-mutant gliobastomas, suggesting the existence of a common set of genes whose expression may be affected by mutations in IDH1 or IDH2 in different types of tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Self-citationTet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA
He, Y., Li, B.-Z., Li, Z., Liu, P., Wang, Y., Tang, Q., Ding, J., Jia, Y., Chen, Z., Li, L., et al. (2011) · Science · doi:10.1126/science.1210944 · Cited by 2,776
Flagged first, then by citations
1 of the 48 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 201–300 of 398
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity
Cai, M., Zhao, J., Ding, Q., & Wei, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24454 · Cited by 30
Kehmann, L., Jördens, M. S., Loosen, S. H., Luedde, T., Roderburg, C., & Leyh, C. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103706 · Cited by 26
Zhang, Y., Esmail, A., Mazzaferro, V., & Abdelrahim, M. (2022) · Cancers · doi:10.3390/cancers14205074 · Cited by 24
Isocitrate dehydrogenase mutations in chondrosarcoma
Azzi, G., Velez, M., & Mathias-Machado, M. C. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000092 · Cited by 23
Connor, A. A., Kodali, S., Abdelrahim, M., Javle, M. M., Brombosz, E. W., & Ghobrial, R. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.996710 · Cited by 23
Seeree, P., Pearngam, P., Kumkate, S., & Janvilisri, T. (2015) · International Journal of Genomics · doi:10.1155/2015/179528 · Cited by 22
The role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 23
Genomic Decoding of Intrahepatic Cholangiocarcinoma Reveals Therapeutic Opportunities
Andersen, J. B., & Thorgeirsson, S. S. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.018 · Cited by 23
Self-citationAhn, D. H., & Bekaii‐Saab, T. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.02.02 · Cited by 23
New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy
Andreozzi, F., Massaro, F., Wittnebel, S., Spilleboudt, C., Lewalle, P., & Salaroli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073887 · Cited by 22
Zhang, X., Chakedis, J. M., Bagante, F., Beal, E. W., Lv, Y., Weiss, M. J., Popescu, I., Marques, H. P., Aldrighetti, L. A., Maithel, S. K., et al. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4199-9 · Cited by 22
Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation
Huang, C., Iwagami, Y., Zou, J., Casulli, S., Lu, S., Nagaoka, K., Ji, C., Ogawa, K., Cao, K. Y., Gao, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.041 · Cited by 22
Lau, D. K., Mouradov, D., Wasenang, W., Luk, I. Y., Scott, C. M., Williams, D. S., Yeung, Y. H., Limpaiboon, T., Iatropoulos, G., Jenkins, L. J., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.044 · Cited by 23
Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview
Yang, W., & Sun, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s297643 · Cited by 22
Liver Cancer Oncogenomics: Opportunities and Dilemmas for Clinical Applications
Marquardt, J. U., & Andersen, J. B. (2015) · Hepatic Oncology · doi:10.2217/hep.14.24 · Cited by 22
Self-citationA perspective on molecular therapy in cholangiocarcinoma: present status and future directions
Andersen, J. B., & Thorgeirsson, S. S. (2013) · Hepatic Oncology · doi:10.2217/hep.13.4 · Cited by 21
Self-citationMolecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma
Høgdall, D., O’Rourke, C. J., Taranta, A., Oliveira, D. V. N. P., & Andersen, J. B. (2016) · Digestive Diseases · doi:10.1159/000444562 · Cited by 21
Self-citationDiagnostic and therapeutic biomarkers in pancreaticobiliary malignancy
Viterbo, D., Gausman, V., & Gonda, T. A. (2016) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v8.i3.128 · Cited by 21
Biliary tract cancer prognostic and predictive genomics
Mondaca, S., Nervi, B., Pinto, M. P., & Abou‐Alfa, G. K. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.07.06 · Cited by 22
Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
Mirallas, O., López-Valbuena, D., García-Illescas, D., Fabregat-Franco, C., Verdaguer, H., Tabernero, J. M., & Macarulla, T. M. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100503 · Cited by 20
RGS10 suppression by DNA methylation is associated with low survival rates in colorectal carcinoma
Caldiran, F. Y., & Çaçan, E. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154007 · Cited by 20
Wang, T., Drill, E. N., Vakiani, E., Pak, L. M., Boerner, T., Aşkan, G., Schvartzman, J. M., Simpson, A. L., Jarnagin, W. R., & Sigel, C. (2019) · Human Pathology · doi:10.1016/j.humpath.2019.05.002 · Cited by 20
Bai, Y., Tong, W., Xie, F., Zhu, L., Wu, H., Shi, R., Wang, L., Yang, L., Liu, Z., Miao, F., et al. (2021) · Aging · doi:10.18632/aging.203249 · Cited by 20
Therapeutic options for intrahepatic cholangiocarcinoma
Bupathi, M., Ahn, D. H., & Bekaii‐Saab, T. (2017) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2016.12.12 · Cited by 18
Luk, I. S. U., Bridgwater, C. M., Yu, A. Y. C., Boila, L. D., Yáñez-Bartolomé, M., Lampano, A., Hulahan, T. S., Boukhali, M., Kathiresan, M., Macarulla, T. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj7685 · Cited by 19
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 18
Baiocchi, L., Sato, K., Ekser, B., Kennedy, L. L., Francis, H., Ceci, L., Lenci, I., Alvaro, D., Franchitto, A., Onori, P., et al. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1854725 · Cited by 17
Molecular heterogeneity in intrahepatic cholangiocarcinoma
Ahn, K. S., & Kang, K. J. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i12.1148 · Cited by 17
Kim, Y.-H., Hong, E.-K., Kong, S., Han, S., Kim, S.-H., Rhee, J., Hwang, S.-K., Park, S., & Kim, T. (2016) · Oncotarget · doi:10.18632/oncotarget.8183 · Cited by 18
Frequency and Prognostic Value of IDH Mutations in Korean Patients With Cholangiocarcinoma
Kim, N. I., Noh, M., Kim, J., Won, E. J., Lee, Y. J., Hur, Y., Moon, K., Lee, K., & Lee, J.-H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01514 · Cited by 16
Self-citationWang, F., Travins, J. M., Lin, Z., Si, Y., Chen, Y., Powe, J., Murray, S., Zhu, D., Artin, E., Größ, S., et al. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9960-y · Cited by 16
Deciphering the multifaceted roles and clinical implications of 2-hydroxyglutarate in cancer
Hao, J., Huang, Z., Zhang, S., Song, K., Wang, J., Gao, C., Fang, Z., & Zhang, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107437 · Cited by 15
Genomics driven precision oncology in advanced biliary tract cancer improves survival
Kumar‐Sinha, C., Vats, P., Tran, N. H., Robinson, D. R., Gunchick, V., Wu, Y., Cao, X., Yu, N., Wang, R., Rabban, E., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100910 · Cited by 15
The role and implication of autophagy in cholangiocarcinoma
Khizar, H., Hu, Y., Wu, Y., & Yang, J. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01631-7 · Cited by 16
Metabolic alteration in tumorigenesis
Yang, H., Xiong, Y., & Guan, K. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4549-2 · Cited by 16
Self-citationBitzer, M., & Malek, N. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00042-9 · Cited by 15
Assessment of liver cancer biomarkers.
Mansouri, V., Razzaghi, M., Nikzamir, A., Ahmadzadeh, A., Iranshahi, M., Haghazali, M., & Hamdieh, M. (2020) · Gastroenterology and hepatology from bed to bench. · Cited by 15
Zhu, Y., Mao, Y., Chen, J., Qiu, Y., Guan, Y., Wang, Z., & He, J. (2021) · Scientific Reports · doi:10.1038/s41598-021-86497-4 · Cited by 15
Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy
Brown, Z. J., Hewitt, D. B., & Pawlik, T. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2703085 · Cited by 15
Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas
Romanidou, O., Kotoula, V., & Fountzilas, G. (2018) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20101 · Cited by 15
Huang, J., Wang, X., Zhu, Y., Wang, Z., Li, J., Xu, D., Wang, S., Li, T., & Lu, L. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.25303 · Cited by 15
An Enzymatic Biosensor for the Detection of D-2-Hydroxyglutaric Acid in Serum and Urine
Wu, B., Li, Z., Kang, Z., Ma, C., Song, H., Lu, F., & Zhu, Z. (2022) · Biosensors · doi:10.3390/bios12020066 · Cited by 15
Consensus Conference on Hilar Cholangiocarcinoma
Forsmark, C. E., Diniz, A. L., & Zhu, A. X. (2015) · HPB · doi:10.1111/hpb.12451 · Cited by 15
Regulation and Functional Significance of 5-Hydroxymethylcytosine in Cancer
Arvinden, V. R., Rao, A. K. D. M., Rajkumar, T., & Mani, S. (2017) · Epigenomes · doi:10.3390/epigenomes1030019 · Cited by 15
Mechanism of cholangiocellular damage and repair during cholestasis
Salas‐Silva, S., Nieves, A. S., Chávez-Rodríguez, L., Gutiérrez‐Ruíz, M. C., Bucio, L., & Gómez-Quiroz, L. E. (2021) · Annals of Hepatology · doi:10.1016/j.aohep.2021.100530 · Cited by 15
Primary Liver Cancers: Connecting the Dots of Cellular Studies and Epidemiology with Metabolomics
Berkemeyer, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032409 · Cited by 16
Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma
Putatunda, V., Jusakul, A., Roberts, L. R., & Wang, X. W. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.013 · Cited by 18
Self-citationTHONGYOO, P., Chindaprasirt, J., Aphivatanasiri, C., Intarawichian, P., Kunprom, W., Kongpetch, S., Techasen, A., Loilome, W., Namwat, N., Titapun, A., et al. (2024) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20492 · Cited by 14
Arnold, A., Bahra, M., Lenze, D., Bradtmöller, M., Guse, K., Gehlhaar, C., Bläker, H., Heppner, F. L., & Koch, A. (2015) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2015.08.003 · Cited by 14
Miyata, T., Yamashita, Y., Baba, Y., Harada, K., Yamao, T., Umezaki, N., Tsukamoto, M., Kitano, Y., Yamamura, K., Arima, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25124 · Cited by 14
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
Wang, J., Zhang, Z.-G., Ding, Z., Dong, W., Liang, H.-F., Chu, L., Zhang, B.-X., & Chen, X. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.04.056 · Cited by 14
Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy
Koustas, E., Trifylli, E.-M., Sarantis, P., Papavassiliou, A. G., & Karamouzis, M. V. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1229 · Cited by 15
Understanding liver regeneration to bring new insights to the mechanisms driving cholangiocarcinoma
Guest, R. V., Boulter, L., Dwyer, B. J., & Forbes, S. J. (2017) · npj Regenerative Medicine · doi:10.1038/s41536-017-0018-z · Cited by 14
Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma?
Cheng, Z., Lei, Z., & Shen, F. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114426 · Cited by 13
Rimini, M., Fabregat-Franco, C., Persano, M., Burgio, V., Bergamo, F., Niger, M., Scartozzi, M., Rapposelli, I. G., Aprile, G., Ratti, F., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-022-00933-7 · Cited by 13
Brandi, G., Deiana, C., Galvani, L., Palloni, A., Ricci, A. D., Rizzo, A., & Tavolari, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1137510 · Cited by 14
Cecchini, M., Pilat, M. J., Uboha, N. V., Azad, N. S., Cho, M. T., Davis, E. J., Rodon, J. A., Tinoco, G., Shapiro, G. I., Khagi, S., et al. (2025) · Cancer · doi:10.1002/cncr.35755 · Cited by 13
Zhu, Y., Chen, J., Kong, W., Mao, L., Kong, W., Zhou, Q., Zhou, Z., Zhu, B., Wang, Z., He, J., et al. (2017) · European Radiology · doi:10.1007/s00330-017-4957-y · Cited by 13
Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications
Lee, S. M., Urman, A. R., & Desai, P. M. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1602260 · Cited by 13
The roles of epigenetic regulation in cholangiocarcinogenesis
Zhong, B., Liao, Q., Wang, X. W., Wang, X., & Zhang, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115290 · Cited by 13
Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice
Ding, N. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i6.2071 · Cited by 13
Ding, L., Ning, S., Hu, W., Xue, Y., & Yu, S. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6595989 · Cited by 12
RetractedChen, W., Xu, D., Liu, Q., Wu, Y., Wang, Y., & Yang, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114697 · Cited by 12
Porreca, V., Barbagallo, C., Corbella, E., Peres, M., Stella, M., Mignogna, G., Maras, B., Ragusa, M., & Mancone, C. (2024) · Cancers · doi:10.3390/cancers16162889 · Cited by 13
The potential role of liver stem cells in initiation of primary liver cancer
Zhi, X., Xiong, J., Zi, X., & Hu, Y. (2016) · Hepatology International · doi:10.1007/s12072-016-9730-9 · Cited by 12
Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy
Li, L., Eid, J. E., Paz, A. C., & Trent, J. C. (2017) · BioDrugs · doi:10.1007/s40259-017-0237-2 · Cited by 12
Genomics of Peritoneal Malignancies
Karunasena, E., Sham, J. G., McMahon, K. W., & Ahuja, N. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2018.02.004 · Cited by 12
Metabolic Rewiring in Adult-Type Diffuse Gliomas
Park, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087348 · Cited by 12
Chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers
Wang, X. A., Bai, Y., Chai, N., Li, Y., Linghu, E., Wang, L., & Liu, Y. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003258 · Cited by 13
Self-citationIDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma
Yao, Y. (2014) · Medical Science Monitor · doi:10.12659/msm.889891 · Cited by 11
Sørensen, M. D., Nielsen, O., Reifenberger, G., & Kristensen, B. W. (2020) · Brain Pathology · doi:10.1111/bpa.12921 · Cited by 11
Racial and Sex Differences in Genomic Profiling of Intrahepatic Cholangiocarcinoma
Tsilimigras, D. I., Stecko, H., Ntanasis‐Stathopoulos, I., & Pawlik, T. M. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-16141-8 · Cited by 10
IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma
Deshmukh, S., Kelly, C. M., & Tinoco, G. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01115-3 · Cited by 15
Harding, J. J., Oh, D., Macarulla, T. M., Goyal, L., Varkaris, A. S., Palmieri, L., Ikeda, M., Kondo, S., Bai, L., Ueno, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0174 · Cited by 10
Genetic Mouse Models as In Vivo Tools for Cholangiocarcinoma Research
Erice, O., Vallejo, A., Ponz‐Sarvisé, M., Saborowski, M., Vogel, A., Calvisi, D. F., Saborowski, A. L., & Vicent, S. (2019) · Cancers · doi:10.3390/cancers11121868 · Cited by 10
Measurement of Oncometabolites d-2-Hydroxyglutaric Acid and l-2-Hydroxyglutaric Acid
Jones, P. M., Boriack, R. L., Struys, E. A., & Rakheja, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7142-8_14 · Cited by 10
Fan, B., Abou‐Alfa, G. K., Zhu, A. X., Pandya, S. S., Jia, H., Yin, F. Q., Gliser, C., Hua, Z., Hossain, M., & Yang, H. Q. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-023-04633-5 · Cited by 9
Lu, X., Xu, S., Deng, Z., Wang, M., & Chen, F. (2025) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaf021 · Cited by 10
Kinzler, M. N., Jeroch, J., Klasen, C., Himmelsbach, V., Koch, C., Finkelmeier, F., Trojan, J., Zeuzem, S., Pession, U., Reis, H., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04603-7 · Cited by 9
Branchi, V., Hosni, R., Kiwitz, L., Ng, S. S., van der Voort, G., Bambi, N., Kleinfelder, E., Esser, L. K., Dold, L., Langhans, B., et al. (2024) · Human Pathology · doi:10.1016/j.humpath.2024.105670 · Cited by 8
Classification of intrahepatic cholangiocarcinoma
Homsi, M. E., Alkhasawneh, A., Arif‐Tiwari, H., Czeyda‐Pommersheim, F., Khasawneh, H., Kierans, A. S., Paspulati, R. M., & Singh, C. (2024) · Abdominal Radiology · doi:10.1007/s00261-024-04732-8 · Cited by 8
IDH Mutant Cholangiocarcinoma: Pathogenesis, Management, and Future Therapies
Bray, A., & Sahai, V. (2025) · Current Oncology · doi:10.3390/curroncol32010044 · Cited by 9
Update for: New developments in systemic therapy for advanced biliary tract cancer
Morizane, C., Ueno, M., Ikeda, M., Okusaka, T., Ishii, H., & Furuse, J. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf016 · Cited by 8
Weber, V., Arnaud, L., Dukić-Stefanović, S., Wenzel, B., Roux, V., Chezal, J., Lai, T. H., Teodoro, R., Kopka, K., Miot-Noirault, É., et al. (2022) · Molecules · doi:10.3390/molecules27123766 · Cited by 8
Signaling pathways as therapeutic targets in biliary tract cancer
Yang, J., Farren, M. R., Ahn, D. H., Bekaii‐Saab, T., & Lesinski, G. B. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1306055 · Cited by 8
Neia, C. P., Scatolini, M., Grosso, E., Lombardi, P., Filippi, R., Raggi, C., Marchiò, C., Cavalloni, G., Aglietta, M., & Leone, F. (2019) · Cancers · doi:10.3390/cancers11040454 · Cited by 8
Treating Biliary Tract Cancers: New Targets and Therapies
Ho, J. K., Fiocco, C., & Spencer, K. R. (2022) · Drugs · doi:10.1007/s40265-022-01808-x · Cited by 8
Targets for therapy in biliary tract cancers: the new horizon of personalized medicine
Iyer, P., Chen, M., Goyal, L., & Denlinger, C. S. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2019.12.11 · Cited by 8
Sinniah, R., Shapses, M. A., Ahmed, M. U., Babiker, H. M., & Chandana, S. R. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1985461 · Cited by 8
Fortina, P., Londin, E., Park, J. Y., & Kricka, L. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7142-8 · Cited by 7
Beyond the Oncogene Revolution: Four New Ways to Combat CancerPreprint
Berger, T., Saunders, M. E., & Mak, T. W. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.031161 · Cited by 8
Oncometabolites as Regulators of DNA Damage Response and Repair
Gueble, S. E., & Bindra, R. S. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.09.004 · Cited by 8
malignancy, A. I. A. H. H., mutations, C. B. T. A. O. V. S. G. A. A. O. I. M. C. A. A. V. S. O. M. S. C. O. I. T. L. 2. D. H. L. T. T. I. O. T. B. T. O. G., (HPCs), W. C. T. S. D. O. T. L. P. T. C. I. M. C. A. S. A. T. H. S. C. (. A. P. C., in, S. A. T. M., of, T. L., in, O. T. M., HPCs, R. T. K. T. C. I. M. P. S.-R. A. B. T. D. O., involving, S. A. T. T. F., & involving, O. T. T. F. (2016) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2016.00019 · Cited by 8
Tateishi, K., & Yamamoto, T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.84543 · Cited by 7
Emerging pathways for precision medicine in management of cholangiocarcinoma
Rahnemai‐Azar, A. A., Abbasi, A., Acher, A. W., Weber, S. M., & Pawlik, T. M. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.08.008 · Cited by 7
Cholangiocarcinoma Therapeutics: An Update
Nguyen, M. L. T., Toàn, N. L., Bożko, M., Bùi, K. C., & Bozko, P. M. (2021) · Current Cancer Drug Targets · doi:10.2174/1568009621666210204152028 · Cited by 8
Current challenges to underpinning the genetic basis for cholangiocarcinoma
Cigliano, A., Chen, X., & Calvisi, D. F. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1915128 · Cited by 9
Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma
Corrigan, L., & Lowery, M. A. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1915765 · Cited by 6
Qian, L., Wang, G., Li, B., Su, H., & Qin, L. (2024) · PeerJ · doi:10.7717/peerj.16740 · Cited by 6
Self-citationNwankwo, E., Guta, A., Cao, S., Yang, J. D., Abdalla, A., Taha, W., Larson, J. J., Yin, J., Gores, G. J., Cleary, S. P., et al. (2024) · Cancers · doi:10.3390/cancers16152720 · Cited by 6
Self-citation
Metadata
- Authors
- Wang, P., Dong, Q., Zhang, C., Kuan, P.-F., Liu, Y., Jeck, W. R., Andersen, J. B., Jiang, W., Savich, G. L., Tan, T.-X., Auman, J. T., Hoskins, J. M., Misher, A. D., Moser, C. D., Yourstone, S. M., Kim, J. W., Cibulskis, K., Getz, G., Hunt, H. V., Thorgeirsson, S. S., Roberts, L. R., Ye, D., Guan, K.-L., Xiong, Y., Qin, L.-X., & Chiang, D. Y.
- Affiliations
- Fudan University (CN)
- Shanghai Medical College of Fudan University (CN)
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- Mayo Clinic (US)
- Atrium Health Wake Forest Baptist (US)
- Broad Institute (US)
- Corresponding author
- Xiong, Y
- Qin, L-X
- Chiang, D Y
- ORCID
- Venue
- Oncogene
- Published
- 2012-07-23
- Volume
- 32
- Issue
- 25
- Pages
- 3091-3100
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC3500578
- OpenAlex
- W2018041848
- Cited by
- 399
- References
- 48
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 26 · 2023: 22 · 2022: 19 · 2021: 38 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 38 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 22 · 2012: 3
- FWCI
- 29.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Fudan University
- National Institutes of Health (5r01ca149569-05)
- National Human Genome Research Institute (R01HG006272)
- National Cancer Institute (R01-CA149569, R01CA163834)
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- IDH mutation, IDH1, IDH2, intrahepatic cholangiocarcinoma, DNA hypermethylation, 5-hydroxymethylcytosine, 5-methylcytosine, p53 activation, overall survival, tumor recurrence, glioblastoma, transcriptional regulation, tumor resection
- MeSH terms
- Base Sequence, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Brain Neoplasms, Glioblastoma, Histones, Humans, Isocitrate Dehydrogenase, Liver Neoplasms, Mutation, Neoplasm Recurrence, Local, Tumor Suppressor Protein p53, Sequence Analysis, DNA, Cholangiocarcinoma, CpG Islands, DNA Methylation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
